X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AMAR REMEDIES with Emami Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES vs EMAMI LTD - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AMAR REMEDIES EMAMI LTD AMAR REMEDIES/
EMAMI LTD
 
P/E (TTM) x -0.5 74.9 - View Chart
P/BV x 0.1 17.8 0.3% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 AMAR REMEDIES   EMAMI LTD
EQUITY SHARE DATA
    AMAR REMEDIES
Jun-12
EMAMI LTD
Mar-16
AMAR REMEDIES/
EMAMI LTD
5-Yr Chart
Click to enlarge
High Rs1641,368 12.0%   
Low Rs86875 9.8%   
Sales per share (Unadj.) Rs261.6115.6 226.3%  
Earnings per share (Unadj.) Rs17.415.8 109.9%  
Cash flow per share (Unadj.) Rs22.327.1 82.4%  
Dividends per share (Unadj.) Rs07.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs100.761.8 162.9%  
Shares outstanding (eoy) m26.16226.97 11.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.59.7 4.9%   
Avg P/E ratio x7.270.9 10.1%  
P/CF ratio (eoy) x5.641.5 13.5%  
Price / Book Value ratio x1.218.1 6.8%  
Dividend payout %044.2 0.0%   
Avg Mkt Cap Rs m3,270254,547 1.3%   
No. of employees `000NA2.9 0.0%   
Total wages/salary Rs m1632,085 7.8%   
Avg. sales/employee Rs ThNM9,113.6-  
Avg. wages/employee Rs ThNM724.1-  
Avg. net profit/employee Rs ThNM1,247.2-  
INCOME DATA
Net Sales Rs m6,84426,238 26.1%  
Other income Rs m21338 6.2%   
Total revenues Rs m6,86526,576 25.8%   
Gross profit Rs m1,1316,924 16.3%  
Depreciation Rs m1282,550 5.0%   
Interest Rs m398540 73.7%   
Profit before tax Rs m6264,171 15.0%   
Minority Interest Rs m04 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-500-   
Tax Rs m121585 20.7%   
Profit after tax Rs m4553,591 12.7%  
Gross profit margin %16.526.4 62.6%  
Effective tax rate %19.314.0 137.8%   
Net profit margin %6.613.7 48.6%  
BALANCE SHEET DATA
Current assets Rs m4,9045,040 97.3%   
Current liabilities Rs m3,5819,127 39.2%   
Net working cap to sales %19.3-15.6 -124.1%  
Current ratio x1.40.6 248.0%  
Inventory Days Days12421 593.4%  
Debtors Days Days10018 553.2%  
Net fixed assets Rs m1,68920,379 8.3%   
Share capital Rs m262227 115.4%   
"Free" reserves Rs m2,35813,024 18.1%   
Net worth Rs m2,63514,031 18.8%   
Long term debt Rs m5073,000 16.9%   
Total assets Rs m6,86226,646 25.8%  
Interest coverage x2.68.7 29.5%   
Debt to equity ratio x0.20.2 90.0%  
Sales to assets ratio x1.01.0 101.3%   
Return on assets %12.415.5 80.2%  
Return on equity %17.325.6 67.5%  
Return on capital %31.027.7 112.0%  
Exports to sales %4.03.8 104.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs m2731,006 27.1%   
Imports (cif) Rs mNA822 0.0%   
Fx inflow Rs m2731,020 26.8%   
Fx outflow Rs m2884 0.2%   
Net fx Rs m271136 199.9%   
CASH FLOW
From Operations Rs m-3135,436 -5.7%  
From Investments Rs m-489-13,070 3.7%  
From Financial Activity Rs m7695,032 15.3%  
Net Cashflow Rs m-33-2,602 1.2%  

Share Holding

Indian Promoters % 25.5 70.6 36.1%  
Foreign collaborators % 0.0 2.2 -  
Indian inst/Mut Fund % 9.2 1.3 707.7%  
FIIs % 0.0 16.8 -  
ADR/GDR % 0.0 0.0 -  
Free float % 65.3 9.2 709.8%  
Shareholders   13,061 25,076 52.1%  
Pledged promoter(s) holding % 99.7 19.5 511.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AMAR REMEDIES With:   HIND. UNILEVER  P&G HYGIENE  GODREJ CONSUMER  BATA INDIA  COLGATE  

Compare AMAR REMEDIES With:   P&G (US)  UNILEVER PLC. (UK)  HYPERMARCAS (Brazil)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AMAR REMEDIES SHARE PRICE


Dec 11, 2013 (Close)

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AMAR REMEDIES 8-QTR ANALYSIS

COMPARE AMAR REMEDIES WITH

MARKET STATS